Phosphodiesterase 9 inhibitor

Last updated

Phosphodiesterase 9 inhibitors or PDE9 inhibitors are a class of drugs that work by inhibiting the activity of PDE9. The first compound with this effect, BAY 73-6691, was reported in 2004. [1] PDE9 inhibitors are under investigation for the treatment of obesity, [2] hepatic fibrosis, [3] Alzheimer's disease, schizophrenia, other psychotic disorders, heart failure, and sickle cell anemia. [1] Drug candidates include CRD-733, [4] osoresnontrine, tovinontrine, and PF-04447943. [1] Cannabidiol acts as a PDE9 inhibitor in vitro. [5] There are no PDE9 inhibitors that have been approved as of 2023. [1]

References

  1. 1 2 3 4 Zheng, Lei; Zhou, Zhong-Zhen (November 2023). "An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential". European Journal of Medicinal Chemistry. 259 115682. doi:10.1016/j.ejmech.2023.115682. PMID   37536210.
  2. ↑ Mishra, Sumita; Sadagopan, Nandhini; Dunkerly-Eyring, Brittany; Rodriguez, Susana; Sarver, Dylan C.; Ceddia, Ryan P.; Murphy, Sean A.; Knutsdottir, Hildur; Jani, Vivek P.; Ashok, Deepthi; Oeing, Christian U.; O’Rourke, Brian; Gangoiti, Jon A.; Sears, Dorothy D.; Wong, G. William; Collins, Sheila; Kass, David A. (1 November 2021). "Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice". The Journal of Clinical Investigation. 131 (21): e148798. doi: 10.1172/JCI148798 . ISSN   0021-9738. PMC   8553561 . PMID   34618683.
  3. ↑ Wu, Yinuo; Wang, Quan; Jiang, Mei-Yan; Huang, Yi-You; Zhu, Ziran; Han, Chuan; Tian, Yi-Jing; Zhang, Bei; Luo, Hai-Bin (8 July 2021). "Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis" . Journal of Medicinal Chemistry. 64 (13): 9537–9549. doi:10.1021/acs.jmedchem.1c00862. ISSN   0022-2623. PMID   34142552.
  4. ↑ Richards, Daniel A.; Aronovitz, Mark J.; Liu, Peiwen; Martin, Gregory L.; Tam, Kelly; Pande, Suchita; Karas, Richard H.; Bloomfield, Daniel M.; Mendelsohn, Michael E.; Blanton, Robert M. (January 2021). "CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload–Induced Heart Failure". Circulation: Heart Failure. 14 (1): e007300. doi: 10.1161/CIRCHEARTFAILURE.120.007300 . ISSN   1941-3289. PMC   8451972 . PMID   33464954.
  5. ↑ Ribaudo, Giovanni; Landucci, Elisa; Giannangeli, Matteo; Mazzantini, Costanza; Maccarinelli, Giuseppina; Mastinu, Andrea; Bonini, Sara Anna; Memo, Maurizio; Pellegrini-Giampietro, Domenico E.; Gianoncelli, Alessandra (2023). "Virtual screening and in vitro experiments highlight cannabidiol as a drug-like phosphodiesterase 9 inhibitor". European Journal of Neuroscience. 57 (12): 1954–1965. doi:10.1111/ejn.15869. hdl: 2158/1322316 . PMID   36382587.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.